Nova’s hepatitis B disease (HBV) model accounts for the virus pathophysiology, including viral replication within hepatocytes and antiviral immune response in chronically infected patients. Nova’s chronic hepatitis B model for exploring and predicting efficacy for novel HBV treatments.


  1. Model description (HBV)
    1. Biological submodels
    2. Drugs that can be tested
    3. Populations of interest
    4. Possible clinical endpoints
  2. Early insights to optimize your trial design

    1. Drug regimen
    2. Combination of treatments
    3. Patient selection


Get your questions answered by downloading the free pdf and learn more about your therapeutic area of interest!

  • Your information will be processed by Nova to send you the content requested. For more information about our processing or to exercise your GDPR rights, see our Privacy Policy
  • This field is for validation purposes and should be left unchanged.